By Shrividya Iyer, PhD, Oncology Lead, US HEOR & RWE, and Sanjay Gupta, PhD, MBA, Department Head, Health Economics, Outcomes Research and Real World Evidence Over the past decade, the term...

By Caroline Ojaimi, Director, US Medical Affairs, Strategy and Operations In late 2019, before the coronavirus pandemic, our Medical Affairs team at Eisai realigned our priorities. We agreed that...

By Luca Dezzani, Vice President, U.S. Medical Affairs, Oncology Business Group In the wake of COVID-19, we were forced into a virtual world that, in many ways, we weren’t entirely ready for. We...

By Asya Kogan, Executive Director, Field Medical, Oncology, Eisai For a medical science liaison (MSL), being “in the field” isn’t what it used to be. Over the years, quite a lot has...

By Tracey Cannova, Associate Medical Director, US Oncology Medical AffairsBy Tracey Cannova, Associate Medical Director, US Oncology Medical Affairs Working in medical affairs is exciting and...

Luca Dezzani is the Vice President of U.S. Medical Affairs for Eisai’s Oncology Business Group. He is responsible for Medical Affairs strategy for the company's oncology portfolio of both...

Dr. Lynn Kramer, CMO, Eisai Neurology, discusses the FDA’s regulatory pathway allowing for the extrapolation of clinical data from adjunctive to monotherapy use in partial-onset seizures, which improves access to epilepsy treatments.

Human genetics is transforming the way new drugs are discovered, giving unprecedented hope for delivering better medicines

Second Publication on the Potential Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”)...

ResponseABILITY is brought to you by Eisai to help shed light on the impact of treatment response on patients with cancer and their families and the physicians who treat them